UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Using multiple cards for rewards can significantly boost your benefits. Find out how to optimize your spending for maximum returns.
17,302 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
America’s energy chart has flipped from import-reliant to resilient. This report explains how something’s different a...
Permanent Portfolio's Michael Cuggino argues Meta can invest heavily in AI without sacrificing profits. He emphasizes...
Geopolitical tensions push on-chain activity higher, with stablecoin liquidity rising as crypto assets resist broader...
Switzerland tightens regulation and traders seek safer, cost-effective access to the forex market. This report highli...
What makes someone a millionaire interview subject and how can you apply their strategies? This guide distills real w...
As hurricane risk and losses climb, lenders are expanding financing options for these round homes resilient designs, ...
When a juggernaut like Fortnite cools its engagement, the ripple effect hits the entire company. This piece digs into...
Anchorage Digital announces a historic custody milestone, expanding regulated access to Tron assets for institutional...
Hedge-fund CIOs say the refining space offers persistent profit potential due to structural capacity limits, even as ...
As 2026 unfolds, Main Street stocks like MAIN reveal how middle-market finance navigates rising rates and credit shif...
Abe Foxman, the longtime director of the Anti-Defamation League, has died at age 86. His 28-year tenure shaped anti-h...